The use of warfarin is problematic, particularly in patients with antiphospholipid syndrome (APS), where prospective clinical studies of new oral anticoagulants (NOAC) are the way forward. Pub Med Curr Rheumatol Rep, 2013 Jun;15(6):331. (Also see: Antiphospholipid Syndrome)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.